Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial [Phase 1]
This is an early-stage (Phase 1) clinical trial evaluating the combination of DS-8201a (trastuzumab deruxtecan) and AZD6738 (camonsertib) fo…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery [Phase 2, Phase 3]
A phase 2/3 trial of Nivolumab and Ipilimumab in esophageal and gastroesophageal junction adenocarcinoma undergoing surgery is currently sus…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer [Phase 3]
This Phase 3 trial is evaluating rilvegostomig in combination with a fluoropyrimidine and trastuzumab deruxtecan as first-line therapy for H…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical study of regorafenib and nivolumab plus chemotherapy for gastric and gastroesophageal junction adenocarcinoma (an…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating trastuzumab deruxtecan, with or without capecitabine and durvalumab, as neoa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study [Phase 2]
A Phase 2 trial (ROBO-CHIP) from Mayo Clinic is evaluating robotic cytoreduction followed by hyperthermic intraperitoneal chemotherapy for g…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment [Phase 3]
ClinicalTrials.gov entry for a Phase 3 study of BL-M05D1 vs investigator's choice in CLDN18.2-positive advanced gastric cancer or gastroesop…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
This Clinical Trials update describes the FAST-GO prospective study evaluating physical function in adults receiving systemic therapy for st…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 trial of neoadjuvant durvalumab plus docetaxel, oxaliplatin and S-1 followed by surgery, with adjuvant durvalumab plus S-1, in poten…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression [Phase 2]
A Phase 2, single-arm exploratory trial evaluating a triple combination of anlotinib, TQB2450, and the SOX chemotherapy regimen as first-lin…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma [Phase 3]
A Phase 3 trial is evaluating mFOLFIRINOX versus mFOLFOX with or without nivolumab for HER2-negative advanced, unresectable, or metastatic e…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating sintilimab with bevacizumab and XELOX/SOX in initially unresectable AFP-positive gastric/GEJ adenocarcinom…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors [Phase 1]
Pfizer's Phase 1 study PF-08046876 is recruiting adults with various advanced solid tumors to evaluate safety and dosing. The trial includes…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer [Phase 3]
A Phase 3 clinical trial comparing proton therapy to photon radiation therapy for esophageal cancer across multiple stages and histologies i…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
An observational study in France evaluating outcomes for patients with advanced gastric and esophageal cancers treated with nivolumab in com…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer [Phase 3]
This entry reports a Phase 3 clinical trial evaluating zolbetuximab in combination with pembrolizumab and chemotherapy for gastric cancer an…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 trial evaluating dynamic ctDNA-guided adjuvant therapy for stage III and IV gastric or gastroesophageal junction adenocarcinoma; cur…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating the adverse events, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, leucovorin, a…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 4]
Phase 4 clinical trial evaluating iparomlimab and tuvonralimab with SOX chemotherapy as first-line treatment for unresectable HER2-negative …
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 clinical trial in China evaluating sintilimab plus chemotherapy versus chemotherapy alone as adjuvant therapy for gastric or gastr…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
This document outlines a real-world, single-arm study protocol evaluating disitamab vedotin in combination with immunotherapy and multimodal…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 [Phase 1]
Phase 1/1b trial evaluating RNDO-564 as a single agent or in combination with pembrolizumab in bladder cancer and nectin-4–associated solid …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity [Phase 2, Phase 3]
A Phase 2/3 clinical trial is evaluating the addition of Paclitaxel administered intraperitoneally with standard chemotherapy for gastric ca…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma [Phase 2]
This Clinical Trials update notes a Phase II neoadjuvant trial combining thymosin alpha-1, a PD-1 inhibitor, and chemoradiotherapy for stage…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: IBI343 in Combination Therapy for Advanced Malignant Solid Tumors [Phase 2]
This is a Phase 2 clinical trial update for IBI343 in combination therapy targeting CLDN18.2-positive advanced solid tumors, including gastr…